CLIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLIR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some fundamental revenue growth, but the price trend is still bearish, there is no strong AI Stock Picker or SwingMax buy signal, options activity is not showing a bullish edge, and there has been no recent news catalyst. For an impatient investor who does not want to wait for a better entry, this is still not an attractive immediate purchase.
Current trend is weak. MACD histogram is negative and still expanding lower, which confirms downside momentum. RSI_6 at 32.34 is near oversold but not yet a clear reversal signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, showing the longer-term trend remains down. Price at 4.925 is just above support at 4.69 and below pivot 5.069, so the stock is sitting in a vulnerable zone rather than breaking out. Near-term price behavior appears mixed to slightly negative.
["Revenue in 2025/Q4 increased sharply to 3.671 million, up 522.20% YoY.", "Gross margin improved to 21.93%, up 46.98% YoY.", "H.C. Wainwright kept a Buy rating and raised the price target to $20 from $2, albeit largely due to the reverse split adjustment.", "Post-market move was positive at +1.97%, suggesting some short-term interest."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Net income remained negative at -311,000 and EPS was -0.06, both worse year over year.", "Bearish technical structure remains in place with MACD weakening and moving averages stacked bearishly.", "Hedge funds and insiders are both neutral, with no meaningful buying trend.", "No recent congress trading data and no notable political/influential person activity."]
In 2025/Q4, ClearSign showed strong top-line growth, with revenue rising to 3.671 million, up 522.20% YoY. Gross margin also improved materially to 21.93%, up 46.98% YoY, which is a positive sign for business quality. However, profitability remains weak: net income was -311,000 and EPS was -0.06, both declining year over year. The latest quarter shows improving sales and margins, but the company is still not profitable.
Recent analyst trend is positive on paper: H.C. Wainwright adjusted its price target to $20 from $2 and maintained a Buy rating on 2026-04-14, though the change was driven by the 1-for-10 reverse split rather than a fresh operational rerating. Wall Street pros appear constructive on valuation upside, but the broader pros-versus-cons view is mixed because the bullish target is not matched by current technical strength or profitability. In short, analysts are more optimistic than the market price action suggests.
